Conditions Value your data Evidence Guides For research labs Sign in Share your story

Evidence / Records patients typically hold

The records patients hold, by condition

The tests, scans, letters and questionnaires clinical guidelines say patients with each condition have, and how often, each with the guideline's own words.

387 figures across 94 conditions, last read 6 Nov 2026. Each row opens the figure with its source and its own words.

Acid reflux (GERD) (4)

Annual review of long-term reflux and dyspepsia medicationan annual reviewNICE CG184, Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management, section 1.5 Reviewing patient care · checked Upper GI endoscopy (with histopathology) to diagnose Barrett's oesophagusconsider it if the person has GORDNICE CG184, Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management, section 1.6.11 · checked Helicobacter pylori test (carbon-13 urea breath test or stool antigen test)'test and treat'NICE CG184, Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management, sections 1.4 and 1.6 · checked Full-dose proton pump inhibitor (PPI) coursefor 4 or 8 weeksNICE CG184, Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management, section 1.6 Interventions for GORD · checked

Acne (3)

12-week treatment review note (improvement and side effects)at 12 weeksNICE NG198, Acne vulgaris: management, section 1 · checked Dermatology referral or clinic letter for acne causing persistent psychological distresspersistent psychological distressNICE NG198, Acne vulgaris: management, section 1 · checked Maintenance treatment reviewafter 12 weeksNICE NG198, Acne vulgaris: management, section 1 · checked

ADHD (5)

Sleep diary while on ADHD medicationwith a sleep diaryNICE NG87 ADHD, recommendations · checked Weight measurement every 6 months in adults on ADHD medicationevery 6 monthsNICE NG87 ADHD, recommendations · checked Heart rate and blood pressure monitoringevery 6 monthsNICE NG87 ADHD, recommendations · checked ADHD medication review (prescription history)at least once a yearNICE NG87 ADHD, recommendations · checked Symptom and adverse effect rating scales (for example Conners' rating scales)standard symptom and adverse effect rating scalesNICE NG87 ADHD, recommendations · checked

Alopecia areata (4)

Skin biopsy in selected cases when clinical findings are inconclusiveskin biopsies can be considered in selected situationsJ Dtsch Dermatol Ges 2026, S3 guideline diagnostics and therapy of alopecia areata, Part 1: Diagnostics and epidemiology · checked Blood tests, thyroid values, ANA titre and vitamin D in alopecia areataif there is a specific anamnestic and/or clinical indicationJ Dtsch Dermatol Ges 2026, S3 guideline diagnostics and therapy of alopecia areata, Part 1: Diagnostics and epidemiology · checked Dermoscopic examination of the alopecic areas to monitor progressought to be performed to monitor the progress of AAJ Dtsch Dermatol Ges 2026, S3 guideline diagnostics and therapy of alopecia areata, Part 1: Diagnostics and epidemiology · checked Patient-reported scales for eyebrow, eyelash and nail involvementClinRo instrument or PRO scalesJ Dtsch Dermatol Ges 2026, S3 guideline diagnostics and therapy of alopecia areata, Part 1: Diagnostics and epidemiology · checked

ALS (4)

Cognitive and behavioural assessmentAt diagnosis, and if there is concern about cognition and behaviourNICE NG42, Motor neurone disease: assessment and management, section 1 · checked Multidisciplinary team (MND clinic) assessment lettersTailor the frequency of the multidisciplinary team assessments to the person's symptoms and needsNICE NG42, Motor neurone disease: assessment and management, section 1 · checked Weight, diet, nutrition and swallowing assessmentAt diagnosis and at multidisciplinary team assessmentsNICE NG42, Motor neurone disease: assessment and management, section 1 · checked Respiratory function monitoring resultsAssess and monitor the person's respiratory function and symptoms.NICE NG42, Motor neurone disease: assessment and management, section 1 · checked

Alzheimer's disease (4)

Blood and urine tests to exclude reversible causesblood and urine testsNICE NG97 Dementia, recommendations · checked Brief cognitive test (for example 6CIT, Mini-Cog)validated brief structured cognitive instrumentNICE NG97 Dementia, recommendations · checked Structural brain imaging (MRI or CT)structural imagingNICE NG97 Dementia, recommendations · checked Neuropsychological testing reportneuropsychological testingNICE NG97 Dementia, recommendations · checked

Amyloidosis (3)

Cardiac magnetic resonance imaging when paraprotein tests are positive and echocardiography is non-diagnosticsuggests performing cardiac magnetic resonance imagingBlood Adv 2026, American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis · checked Serum and urine immunofixation electrophoresis and serum free light chains in suspected cardiac amyloidosisserum and urine immunofixation electrophoresisBlood Adv 2026, American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis · checked Tissue biopsy (fat-pad, bone marrow or endomyocardial) to diagnose AL amyloidosisfat-pad sampling and bone marrow (BM) biopsyBlood Adv 2026, American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis · checked

Ankylosing spondylitis (5)

BASDAI disease activity questionnaire and spinal pain VASBath Ankylosing Spondylitis Disease Activity Index (BASDAI)NICE NG65, Spondyloarthritis in over 16s: diagnosis and management, recommendations · checked Osteoporosis assessment (DEXA bone density scan)every 2 yearsNICE NG65, Spondyloarthritis in over 16s: diagnosis and management, recommendations · checked HLA-B27 blood testHLA-B27 testNICE NG65, Spondyloarthritis in over 16s: diagnosis and management, recommendations · checked MRI of spine and sacroiliac joints (inflammatory back pain protocol)unenhanced MRINICE NG65, Spondyloarthritis in over 16s: diagnosis and management, recommendations · checked Plain X-ray of the sacroiliac jointsplain film X-rayNICE NG65, Spondyloarthritis in over 16s: diagnosis and management, recommendations · checked

Anxiety (5)

Review within 1 week of first prescribing, with weekly monitoring of suicidal thinkingweekly for the first monthNICE CG113 Generalised anxiety disorder and panic disorder in adults, recommendations · checked Routine outcome measures during psychological treatmentroutine outcome measuresNICE CG113 Generalised anxiety disorder and panic disorder in adults, recommendations · checked Anxiety drug treatment review (prescription history), generalised anxiety disorderevery 3 months thereafterNICE CG113 Generalised anxiety disorder and panic disorder in adults, recommendations · checked GAD-2 anxiety questionnaire2-item Generalized Anxiety Disorder scale (GAD-2)NICE CG113 Generalised anxiety disorder and panic disorder in adults, recommendations · checked Anxiety drug treatment review (prescription history), panic disorder8- to 12-week intervalsNICE CG113 Generalised anxiety disorder and panic disorder in adults, recommendations · checked

Asthma (5)

Annual asthma review with written personalised action planat least annuallyNICE NG245, Asthma: diagnosis, monitoring and chronic asthma management, objective tests for adults · checked Adherence check from prescription records and inhaler techniqueat every asthma-related healthcare reviewNICE NG245, Asthma: diagnosis, monitoring and chronic asthma management, objective tests for adults · checked Asthma control questionnaire (ACQ or ACT)at any asthma reviewNICE NG245, Asthma: diagnosis, monitoring and chronic asthma management, monitoring · checked Blood eosinophil count or FeNO testat diagnosis (repeat as clinically needed)NICE NG245, Asthma: diagnosis, monitoring and chronic asthma management, objective tests for adults · checked Spirometry with bronchodilator reversibilityat diagnosis (repeat as clinically needed)NICE NG245, Asthma: diagnosis, monitoring and chronic asthma management, objective tests for adults · checked

Atrial fibrillation (4)

Ambulatory ECG monitorwhen paroxysmal AF is suspectedNICE NG196, Atrial fibrillation: diagnosis and management, section 1.1 · checked Anticoagulation reviewat least annuallyNICE NG196, Atrial fibrillation: diagnosis and management, section 1.7 · checked 12-lead ECGat diagnosisNICE NG196, Atrial fibrillation: diagnosis and management, section 1.1 · checked Transthoracic echocardiogrambaseline, and before rhythm controlNICE NG196, Atrial fibrillation: diagnosis and management, section 1.7 · checked

Autism (4)

Written report of the autism diagnostic assessment (children and young people), shared with the GPa written report of the autism diagnostic assessmentNICE CG128, Autism spectrum disorder in under 19s: recognition, referral and diagnosis, recommendations 1.8.4 and 1.8.5 · checked Antipsychotic prescription for behaviour that challenges, with an early reviewafter 3–4 weeksNICE CG142, Autism spectrum disorder in adults: diagnosis and management, recommendation 1.5.7 · checked Autism-Spectrum Quotient 10-item questionnaire (AQ-10) for adults with possible autismscores 6 or above on the AQ-10NICE CG142, Autism spectrum disorder in adults: diagnosis and management, recommendation 1.2.3 · checked Care plan based on the comprehensive autism assessment (adults)Develop a care plan based on the comprehensive assessmentNICE CG142, Autism spectrum disorder in adults: diagnosis and management, recommendation 1.2.13 · checked

Back pain (3)

Spine imaging in non-specialist settings, not routineDo not routinely offer imaging in a non-specialist settingNICE NG59 Low back pain and sciatica in over 16s, recommendations · checked Spine MRI or imaging in specialist careonly if the result is likely to change managementNICE NG59 Low back pain and sciatica in over 16s, recommendations · checked STarT Back risk stratification questionnaireSTarT BackNICE NG59 Low back pain and sciatica in over 16s, recommendations · checked

Bipolar disorder (5)

Fasting glucose or HbA1c and lipid profile when on an antipsychoticat 12 weeksNICE CG185 Bipolar disorder, recommendations · checked Self-monitoring of mood, thoughts and behaviourself‑monitoring of mood, thoughts and behaviourNICE CG185 Bipolar disorder, recommendations · checked Annual physical health check blood tests (HbA1c or fasting glucose, lipid profile, liver, renal and thyroid function)at least annuallyNICE CG185 Bipolar disorder, recommendations · checked Annual review of treatment and care including medicationat least annuallyNICE CG185 Bipolar disorder, recommendations · checked Plasma lithium levelweekly until the levels are stableNICE CG185 Bipolar disorder, recommendations · checked

Bladder cancer (3)

Follow-up cystoscopy for intermediate-risk non-muscle-invasive bladder cancerat 3, 9 and 18 months, and once a year thereafterNICE NG2, Bladder cancer: diagnosis and management, recommendations · checked CT or MRI staging for muscle-invasive or high-risk bladder cancer being assessed for radical treatmentoffer CT or MRI stagingNICE NG2, Bladder cancer: diagnosis and management, recommendations · checked Histology of the resected bladder tumour (type, grade, stage, carcinoma in situ)histological type, grade, stage and presence (or absence) of flat urotheliumNICE NG2, Bladder cancer: diagnosis and management, recommendations · checked

Breast cancer (5)

BRCA1 and BRCA2 genetic test for women under 50 with triple-negative breast cancerBRCA1 and BRCA2 mutationsNICE NG101 Early and locally advanced breast cancer, recommendations · checked Sentinel lymph node biopsy pathologysentinel lymph node biopsy (SLNB)NICE NG101 Early and locally advanced breast cancer, recommendations · checked Pathology report with ER, PR and HER2 statusoestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)NICE NG101 Early and locally advanced breast cancer, recommendations · checked Mammogramannual mammography for 5 yearsNICE NG101 Early and locally advanced breast cancer, recommendations · checked Breast MRI before surgeryMRI of the breastNICE NG101 Early and locally advanced breast cancer, recommendations · checked

Burnout (4)

Four-Dimensional Symptom Questionnaire (4DKL) to support the diagnosis of work strain and burnout4DKLMultidisciplinaire richtlijn overspanning en burnout voor eerstelijns professionals (LVE, NHG and NVAB, the Dutch occupational physicians' association, 2011), section 4.3 Aanbevelingen · checked Physical examination and additional tests (such as blood tests) for burnout: not indicatedNiet geïndiceerdNHG-Standaard Overspanning en burn-out (Dutch College of General Practitioners), as published in Huisarts en Wetenschap, November 2018, Richtlijnen diagnostiek · checked Burnout questionnaire covering the three ICD-11 dimensions (exhaustion, cynicism, reduced efficacy)three dimensionsWHO, Burn-out an occupational phenomenon: International Classification of Diseases · checked Maslach Burnout Inventory (Human Services Survey) score22-item surveyBurnout: A Review of Theory and Measurement (Edu-Pérez et al., Int J Environ Res Public Health 2022), section 6.2 · checked

Celiac disease (5)

Annual coeliac reviewannuallyNICE NG20, Coeliac disease: recognition, assessment and management, section 1.4 · checked Endoscopic intestinal biopsyat diagnosisNICE NG20, Coeliac disease: recognition, assessment and management, section 1.1 · checked DEXA bone scan assessment when concerns are raised at reviewdual‑energy X‑ray absorptiometry (DEXA) scanNICE NG20, Coeliac disease: recognition, assessment and management, section 1.4 · checked IgA endomysial antibody (EMA) test when tTG is weakly positiveIgA endomysial antibodies (EMA)NICE NG20, Coeliac disease: recognition, assessment and management, section 1.1 · checked IgA tissue transglutaminase (tTG) antibody blood testat diagnosisNICE NG20, Coeliac disease: recognition, assessment and management, section 1.1 · checked

Chronic kidney disease (5)

Urine albumin:creatinine ratio (ACR)individualised by risk of progressionNICE NG203, Chronic kidney disease: assessment and management, section 1.1 · checked Haemoglobin monitoring in anaemia of CKDevery 1 to 3 months in the maintenance phase of ESA therapyNICE NG203, Chronic kidney disease: assessment and management, section 1.1 · checked eGFR blood testminimum number of checks per year depends on GFR and ACR categoryNICE NG203, Chronic kidney disease: assessment and management, table 2 · checked GFR monitoring for people on kidney-affecting medicinesat least annuallyNICE NG203, Chronic kidney disease: assessment and management, section 1.1 · checked Serum potassium and eGFR around renin-angiotensin system antagonist treatmentbetween 1 and 2 weeks after startingNICE NG203, Chronic kidney disease: assessment and management, section 1.1 · checked

Chronic pain (5)

Prescription drug monitoring program (PDMP) review of controlled-substance prescriptionsevery 3 months or more frequentlyDowell et al., CDC Clinical Practice Guideline for Prescribing Opioids for Pain: United States, 2022, MMWR Recomm Rep 2022, Recommendation 9 · checked PEG pain and function questionnaire (3 items) at reassessmentevery 3 months or more frequentlyDowell et al., CDC Clinical Practice Guideline for Prescribing Opioids for Pain: United States, 2022, MMWR Recomm Rep 2022, Recommendation 7 · checked Urine toxicology testat least annuallyDowell et al., CDC Clinical Practice Guideline for Prescribing Opioids for Pain: United States, 2022, MMWR Recomm Rep 2022, Recommendation 10 · checked Antidepressant prescription for chronic primary painfor people aged 18 years and overNICE NG193, Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain, section 1.2 Managing chronic primary pain · checked Care and support plan from a person-centred pain assessmentreview the care and support planNICE NG193, Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain, section 1.1 · checked

Colorectal cancer (5)

Adjuvant chemotherapy for stage 3 rectal cancer (CAPOX)for 3 monthsNICE NG151 Colorectal cancer, recommendations · checked Preoperative radiotherapy or chemoradiotherapy for rectal cancerpreoperative radiotherapy or chemoradiotherapyNICE NG151 Colorectal cancer, recommendations · checked CEA blood test follow-upfor the first 3 yearsNICE NG151 Colorectal cancer, recommendations · checked CT scan of chest, abdomen and pelvis follow-upCT scan of the chest, abdomen and pelvisNICE NG151 Colorectal cancer, recommendations · checked RAS and BRAF V600E mutation test (pathology)RAS and BRAF V600E mutationsNICE NG151 Colorectal cancer, recommendations · checked

COPD (4)

COPD reviewat least once per year, more often if indicatedNICE NG115, Chronic obstructive pulmonary disease in over 16s, follow-up · checked Annual flu vaccination and pneumococcal vaccinationannual flu vaccinationNICE NG115, Chronic obstructive pulmonary disease in over 16s, managing stable COPD · checked Long-term oxygen therapy review with pulse oximetryat least once per yearNICE NG115, Chronic obstructive pulmonary disease in over 16s, oxygen · checked Review for very severe COPDat least twice per yearNICE NG115, Chronic obstructive pulmonary disease in over 16s, follow-up · checked

Coronary heart disease (5)

Left ventricular function assessment (echocardiogram)after a heart attack (STEMI)NICE NG185, Acute coronary syndromes, STEMI · checked Resting 12-lead ECG in the risk assessment of acute coronary syndromea resting 12‑lead ECGNICE NG185, Acute coronary syndromes, STEMI · checked Full lipid profileannuallyNICE NG238, Cardiovascular disease: risk assessment and reduction, including lipid modification, annual medication review · checked Liver transaminase after starting or changing lipid-lowering treatmentat 2 to 3 months after starting or changing lipid-lowering treatmentNICE NG238, Cardiovascular disease: risk assessment and reduction, including lipid modification, annual medication review · checked Annual medication review (lipid-lowering treatment)annuallyNICE NG238, Cardiovascular disease: risk assessment and reduction, including lipid modification, annual medication review · checked

Crohn's disease (5)

Surveillance colonoscopyevery 5 years (low risk), 3 years (intermediate risk), 1 year (high risk)NICE CG118, Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn's disease or adenomas · checked Review of infliximab or adalimumab treatmentat least every 12 monthsNICE NG129, Crohn's disease: management, section 1.2 · checked Bone mineral density monitoring in children and young people with risk factorsbone mineral densityNICE NG129, Crohn's disease: management, section 1.2 · checked Neutropenia monitoring on azathioprine or mercaptopurineMonitor for neutropeniaNICE NG129, Crohn's disease: management, section 1.2 · checked Blood monitoring for azathioprine, mercaptopurine or methotrexateas advised in the BNFNICE NG129, Crohn's disease: management, section 1.2 · checked

Cystic fibrosis (3)

Routine clinic review (adults)every 3 to 6 months as adultsNICE NG78 Cystic fibrosis, recommendations · checked Cystic-fibrosis-related diabetes testannually from 10 years of ageNICE NG78 Cystic fibrosis, recommendations · checked Pulmonary monitoring review (adults with lung disease)at least every 3 monthsNICE NG78 Cystic fibrosis, recommendations · checked

Depression (5)

Routine outcome monitoring with validated sessional measures (for example PHQ-9)validated sessional outcome measuresNICE NG222 Depression in adults, recommendations · checked Review 1 week after starting or increasing an antidepressant, for suicidality1 week after starting the antidepressant medicationNICE NG222 Depression in adults, recommendations · checked Antidepressant medication review (prescription history)at least every 6 monthsNICE NG222 Depression in adults, recommendations · checked Weight, renal and thyroid function and calcium levels while on lithiumat least every 6 monthsNICE NG222 Depression in adults, recommendations · checked Validated symptom, function or disability measure (for example PHQ-9 questionnaire)validated measureNICE NG222 Depression in adults, recommendations · checked

Eating disorders (5)

Annual physical and mental health review with relevant blood tests (anorexia nervosa not in treatment)at least annuallyNICE NG69, Eating disorders: recognition and treatment, recommendation 1.10.10 · checked Bone mineral density scan in anorexia nervosaafter 2 years of underweight in adultsNICE NG69, Eating disorders: recognition and treatment, recommendation 1.10.15 · checked ECG monitoring while taking medication that could affect the heartOffer electrocardiogram (ECG) monitoringNICE NG69, Eating disorders: recognition and treatment, recommendation 1.8.17 · checked Fluid and electrolyte assessment in people who vomit or misuse laxatives or diureticsAssess fluid and electrolyte balanceNICE NG69, Eating disorders: recognition and treatment, recommendation 1.10.1 · checked Self-monitoring record of dietary intake and thoughts during CBT-ED for anorexia nervosaup to 40 sessions over 40 weeksNICE NG69, Eating disorders: recognition and treatment, recommendation 1.3.5 · checked

Eczema (5)

Review of non-sedating antihistamine trialreview every 3 monthsNICE CG57 Atopic eczema in under 12s, recommendations · checked Diagnosis of atopic eczema from history and skin findingsitchy skin condition plus 3 or more of the followingNICE CG57 Atopic eczema in under 12s, recommendations · checked Allergy tests, only when a food or inhalant allergy is suspectedmost children with mild atopic eczema do not need to have tests for allergiesNICE CG57 Atopic eczema in under 12s, recommendations · checked Repeat prescription review (prescription history)at least once a yearNICE CG57 Atopic eczema in under 12s, recommendations · checked Severity and quality-of-life assessment (children)at each consultationNICE CG57 Atopic eczema in under 12s, recommendations · checked

Ehlers-Danlos syndrome (4)

Generalized Joint Hypermobility 5-Point Questionnaire (5PQ)at least 2 positive itemsEhlers-Danlos Society, 2017 International Classification of the Ehlers-Danlos Syndromes (slide set, 15 March 2017) · checked Beighton score (generalized joint hypermobility examination)Beighton ScoreEhlers-Danlos Society, 2017 International Classification of the Ehlers-Danlos Syndromes (slide set, 15 March 2017) · checked COL5A1 and COL5A2 gene test report (classical EDS)more than 90% of the patientsEhlers-Danlos Society, 2017 International Classification of the Ehlers-Danlos Syndromes (slide set, 15 March 2017) · checked Echocardiogram report (mitral valve prolapse, aortic root dilatation)Aortic root dilatation with Z-score >+2Ehlers-Danlos Society, 2017 International Classification of the Ehlers-Danlos Syndromes (slide set, 15 March 2017) · checked

Endometrial cancer (2)

Suspected cancer pathway referral for post-menopausal bleedingsuspected cancer pathway referralNICE NG12, Suspected cancer: recognition and referral, recommendations · checked Urgent direct access ultrasound scan to assess for endometrial cancerurgent, direct access ultrasound scanNICE NG12, Suspected cancer: recognition and referral, recommendations · checked

Endometriosis (5)

Hormonal treatment prescription (combined pill or progestogen)hormonal treatmentNICE NG73, Endometriosis: diagnosis and management, section 1.5 · checked Diagnostic laparoscopy reportif imaging is normal but endometriosis is suspectedNICE NG73, Endometriosis: diagnosis and management, section 1.5 · checked Specialist ultrasound or pelvic MRI for deep endometriosiswhen deep endometriosis is suspectedNICE NG73, Endometriosis: diagnosis and management, section 1.5 · checked Pain and symptom diarypain and symptom diaryNICE NG73, Endometriosis: diagnosis and management, section 1.5 · checked Transvaginal ultrasound scanat suspected diagnosisNICE NG73, Endometriosis: diagnosis and management, section 1.5 · checked

Epilepsy (4)

12-lead ECG after a first seizureafter a first suspected seizureNICE NG217, Epilepsies in children, young people and adults, section 1 · checked EEG (electroencephalogram)at diagnosisNICE NG217, Epilepsies in children, young people and adults, section 1 · checked Epilepsy monitoring reviewregular (at least annual)NICE NG217, Epilepsies in children, young people and adults, section 4.4 Monitoring and review · checked MRI of the brainat diagnosisNICE NG217, Epilepsies in children, young people and adults, section 1 · checked

Fatty liver disease (3)

Liver ultrasound to diagnose MASLD in children and young peopleOffer a liver ultrasound to test children and young people for MASLDNICE NG49, MASLD: assessment and management, recommendation 1.2.1 · checked Repeat ELF test for people with an ELF score below 10.51every 3 years to adults every 2 years to children and young peopleNICE NG49, MASLD: assessment and management, recommendation 1.3.7 · checked Enhanced liver fibrosis (ELF) blood test after MASLD diagnosisConsider using the enhanced liver fibrosis (ELF) testNICE NG49, MASLD: assessment and management, recommendation 1.3.2 · checked

Fibromyalgia (5)

Diagnostic checklist (modified ACR 2010 criteria, no tender point exam needed)(modified) ACR 2010 diagnostic criteriaClassification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines (Canadian, German, Israeli), Evid Based Complement Alternat Med 2013 · checked Screening for symptoms of anxiety and depression at initial evaluationas part of the initial evaluationClassification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines (Canadian, German, Israeli), Evid Based Complement Alternat Med 2013 · checked Diagnostic label and explanation of the disorder, treatment strategy and outcomeafter initial diagnosisClassification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines (Canadian, German, Israeli), Evid Based Complement Alternat Med 2013 · checked Selected laboratory tests to exclude another diseaseselected laboratory testsClassification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines (Canadian, German, Israeli), Evid Based Complement Alternat Med 2013 · checked Fibromyalgia survey questionnaire (symptom severity and widespread pain index)fibromyalgia survey questionnaireClassification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines (Canadian, German, Israeli), Evid Based Complement Alternat Med 2013 · checked

Gestational diabetes (5)

Ultrasound monitoring of fetal growth and amniotic fluid volumeevery 4 weeks from 28 to 36 weeksNICE NG3, Diabetes in pregnancy: management from preconception to the postnatal period, section 1.4 Antenatal care · checked Annual HbA1c test after gestational diabetesan annual HbA1c testNICE NG3, Diabetes in pregnancy: management from preconception to the postnatal period, section 1.6 Postnatal care · checked Home capillary blood glucose readings (fasting and 1-hour post-meal)dailyNICE NG3, Diabetes in pregnancy: management from preconception to the postnatal period, section 1.3 Blood glucose monitoring · checked 75-g 2-hour oral glucose tolerance test (OGTT)at 24 to 28 weeksNICE NG3, Diabetes in pregnancy: management from preconception to the postnatal period, section 1.2 Gestational diabetes · checked Postnatal fasting plasma glucose test6 to 13 weeks after the birthNICE NG3, Diabetes in pregnancy: management from preconception to the postnatal period, section 1.6 Postnatal care · checked

Glaucoma (4)

Glaucoma reassessment visit for stable COAGbetween 12 months and 18 months (low risk), between 6 months and 12 months (high risk)NICE NG81, Glaucoma: diagnosis and management, recommendations · checked Optic nerve head image (stereo photograph or OCT) at diagnosisat diagnosisNICE NG81, Glaucoma: diagnosis and management, recommendations · checked Prostaglandin analogue eye drop prescriptiongeneric PGANICE NG81, Glaucoma: diagnosis and management, recommendations · checked Referral letter with all examination and test resultswith the referralNICE NG81, Glaucoma: diagnosis and management, recommendations · checked

Gout (5)

Joint aspiration and synovial fluid microscopyif a diagnosis of gout remains uncertain or unconfirmedNICE NG219, Gout: diagnosis and management, recommendations · checked X-ray, ultrasound or dual-energy CT of affected jointsX-ray, ultrasound or dual-energy CTNICE NG219, Gout: diagnosis and management, recommendations · checked Annual serum urate monitoring on urate-lowering therapyannualNICE NG219, Gout: diagnosis and management, recommendations · checked Serum urate blood test to confirm the diagnosisto confirm the clinical diagnosisNICE NG219, Gout: diagnosis and management, recommendations · checked Serum urate blood tests while urate-lowering therapy is titratedmonthlyNICE NG219, Gout: diagnosis and management, recommendations · checked

Haemophilia (3)

Annual musculoskeletal and overall health assessmentat least annuallyWorld Federation of Hemophilia, WFH Guidelines for the Management of Hemophilia, 3rd edition (Haemophilia 2020), chapter 11 · checked Bleed log documented in real time and reviewed at least annuallyreviewed together at least annuallyWorld Federation of Hemophilia, WFH Guidelines for the Management of Hemophilia, 3rd edition (Haemophilia 2020), chapter 11 · checked Inhibitor screening in newly diagnosed hemophilia Aat least every 6-12 months, and then annuallyWorld Federation of Hemophilia, WFH Guidelines for the Management of Hemophilia, 3rd edition (Haemophilia 2020), chapter 8 · checked

Heart failure (4)

Transthoracic echocardiogramat diagnosisNICE NG106, Chronic heart failure in adults: diagnosis and management, section 1.2 · checked NT-proBNP blood testat suspected diagnosisNICE NG106, Chronic heart failure in adults: diagnosis and management, section 1.2 · checked Kidney function and electrolytes blood testevery 3 to 6 months once the maximum tolerated dose has been establishedNICE NG106, Chronic heart failure in adults: diagnosis and management, section 1.7 · checked Heart failure care review in primary careat least every 6 monthsNICE NG106, Chronic heart failure in adults: diagnosis and management, section 1.1 · checked

Hepatitis B (4)

HBV DNA, quantitative HBsAg and HBeAg status on tenofovirthen every 6 monthsNICE CG165, Hepatitis B (chronic): diagnosis and management, recommendation 1.6.16 · checked Annual transient elastography (liver stiffness scan) for adults not on antiviral treatmentan annual reassessment of liver disease using transient elastographyNICE CG165, Hepatitis B (chronic): diagnosis and management, recommendation 1.3.8 · checked Liver ultrasound and alpha-fetoprotein surveillance for liver cancer6-monthlyNICE CG165, Hepatitis B (chronic): diagnosis and management, recommendation 1.7.1 · checked Full blood count, liver and renal function, and phosphate on tenofovirthen every 3 monthsNICE CG165, Hepatitis B (chronic): diagnosis and management, recommendation 1.6.15 · checked

Hepatitis C (4)

Direct-acting antiviral course (glecaprevir/pibrentasvir or sofosbuvir/velpatasvir)8 weeks of glecaprevir/pibrentasvir or 12 weeks of sofosbuvir/velpatasvirAASLD-IDSA, Hepatitis C Guidance 2019 Update, Hepatology 2020 (simplified treatment algorithm) · checked Liver ultrasound surveillance for liver cancer after treatment, in cirrhosisevery 6 monthsAASLD-IDSA, Hepatitis C Guidance 2019 Update, Hepatology 2020 (simplified treatment algorithm) · checked Quantitative HCV RNA (with HIV and HBsAg tests) before treatmentany time prior to initiating DAA therapyAASLD-IDSA, Hepatitis C Guidance 2019 Update, Hepatology 2020 (simplified treatment algorithm) · checked HCV RNA and aminotransferase test to confirm cure (SVR)12 or more weeks after completing DAA treatmentAASLD-IDSA, Hepatitis C Guidance 2019 Update, Hepatology 2020 (simplified treatment algorithm) · checked

High blood pressure (4)

Ambulatory blood pressure monitoring (ABPM)at diagnosisNICE NG136, Hypertension in adults: diagnosis and management, section 1.2 · checked Blood tests at diagnosis (HbA1c, electrolytes, creatinine, eGFR, cholesterol)at diagnosisNICE NG136, Hypertension in adults: diagnosis and management, section 1.3 · checked 12-lead ECGat diagnosisNICE NG136, Hypertension in adults: diagnosis and management, section 1.3 · checked Urine albumin to creatinine ratioat diagnosisNICE NG136, Hypertension in adults: diagnosis and management, section 1.3 · checked

HIV (5)

Baseline CD4 cell countbaseline CD4 cell count testing should be performedWHO Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring (2021), rapid ART initiation · checked Cryptococcal antigen screening before starting ART with low CD4CD4 count <100 cells/mm3WHO Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring (2021), rapid ART initiation · checked Dolutegravir-based first-line antiretroviral therapy prescriptionpreferred first-line regimenWHO Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring (2021), first-line ART · checked TB preventive treatment prescriptionTB preventive treatmentWHO Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring (2021), first-line ART · checked HIV viral load test on antiretroviral therapyby six months, at 12 months and then every 12 months thereafterWHO Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring (2021), timing of treatment monitoring · checked

Huntington's disease (3)

HTT gene CAG repeat length test reportalleles with 40 or more repeats are fully penetrantBachoud-Lévi et al., International Guidelines for the Treatment of Huntington's Disease, Frontiers in Neurology 2019 · checked Malnutrition screening (MUST) and weight recordsScreening tools for malnutrition [e.g., malnutrition Universal Screening Tool (MUST)] are recommended.Bachoud-Lévi et al., International Guidelines for the Treatment of Huntington's Disease, Frontiers in Neurology 2019 · checked Swallowing assessment (speech and language therapist)Regular assessment of swallowing disorders should be provided throughout the progression of the diseaseBachoud-Lévi et al., International Guidelines for the Treatment of Huntington's Disease, Frontiers in Neurology 2019 · checked

Hypothyroidism (5)

Free T4 test when symptoms persist on levothyroxineFT4 as well as TSHNICE NG145, Thyroid disease: assessment and management, section 1.3 · checked TSH and FT4 monitoring in untreated subclinical hypothyroidismonce a year if they have features suggesting underlying thyroid diseaseNICE NG145, Thyroid disease: assessment and management, section 1.3 · checked Thyroid peroxidase antibodies (TPOAb)once (do not repeat)NICE NG145, Thyroid disease: assessment and management, section 1.2 · checked TSH blood test for diagnosisat diagnosisNICE NG145, Thyroid disease: assessment and management, section 1.2 · checked TSH blood test on levothyroxineevery 3 months until stable, then once a yearNICE NG145, Thyroid disease: assessment and management, section 1.3 · checked

IgA nephropathy (3)

Kidney biopsy for diagnosis of IgA nephropathykidney biopsy is recommendedClin Kidney J 2025, The 2025 KDIGO IgA nephropathy guideline update: an ERA Immunonephrology Working Group perspective · checked MEST-C histological score on the kidney biopsyMEST-C scoring systemClin Kidney J 2025, The 2025 KDIGO IgA nephropathy guideline update: an ERA Immunonephrology Working Group perspective · checked Proteinuria measurement to guide risk and treatment in IgA nephropathyaiming for complete remissionClin Kidney J 2025, The 2025 KDIGO IgA nephropathy guideline update: an ERA Immunonephrology Working Group perspective · checked

Infertility (4)

AMH blood test or antral follicle count (ovarian reserve)AMH measurement or antral follicle count (AFC)NICE NG257 Fertility problems, investigation of fertility problems · checked Hysterosalpingography (HSG) tubal patency scanhysterosalpingography (HSG)NICE NG257 Fertility problems, investigation of fertility problems · checked Mid-luteal serum progesterone blood testmid-luteal phase of their cycle (day 21 of a 28-day cycle)NICE NG257 Fertility problems, investigation of fertility problems · checked Semen analysisrepeat confirmatory testNICE NG257 Fertility problems, investigation of fertility problems · checked

Iron deficiency anaemia (5)

Blood count monitoring for recurrent IDAperhaps every 6 months initiallySnook et al., British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults, Gut 2021 · checked Coeliac disease screening and urinalysisinitial investigation of confirmed IDASnook et al., British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults, Gut 2021 · checked Gastroscopy and colonoscopy (bidirectional endoscopy)first-line GI investigationsSnook et al., British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults, Gut 2021 · checked Haemoglobin check for response to oral ironin the first 4 weeksSnook et al., British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults, Gut 2021 · checked Serum ferritin blood testthe single most useful marker of IDASnook et al., British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults, Gut 2021 · checked

Irritable bowel syndrome (5)

Annual patient review of IBS symptomsannual patient reviewNICE CG61 Irritable bowel syndrome in adults, recommendations · checked Review of second-line tricyclic antidepressantreview regularlyNICE CG61 Irritable bowel syndrome in adults, recommendations · checked Coeliac disease antibody test (EMA or TTG)antibody testing for coeliac diseaseNICE CG61 Irritable bowel syndrome in adults, recommendations · checked C-reactive protein and ESR or plasma viscosityc-reactive protein (CRP)NICE CG61 Irritable bowel syndrome in adults, recommendations · checked Full blood countfull blood count (FBC)NICE CG61 Irritable bowel syndrome in adults, recommendations · checked

Kidney stones (4)

24-hour urine collection (metabolic evaluation)every twelve monthsEAU Guidelines on Urolithiasis (2026 edition), Metabolic Evaluation and Recurrence Prevention · checked Low-dose non-contrast CT for suspected renal colicwithin 24 hours of presentationNICE NG118, Renal and ureteric stones: assessment and management, section 1.1 Diagnostic imaging · checked Serum calcium blood testmeasure serum calciumNICE NG118, Renal and ureteric stones: assessment and management, section 1.7 Metabolic testing · checked Stone composition analysisconsider stone analysisNICE NG118, Renal and ureteric stones: assessment and management, section 1.7 Metabolic testing · checked

Leukaemia (3)

Blood count and physical examination while early-stage chronic lymphocytic leukaemia is watched3- to 12-monthly controls by blood countEichhorst and Ghia, EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia (HemaSphere 2020) · checked Very urgent full blood count when leukaemia is suspected in an adultvery urgent full blood countNICE NG12, Suspected cancer: recognition and referral, recommendation 1.10.1 · checked Integrated diagnostic report from a specialist haematological malignancy diagnostic service (SIHMDS)all new diagnosesNICE NG47, Haematological cancers: improving outcomes, recommendation 1.3.17 · checked

Long COVID (3)

Blood tests (full blood count, kidney and liver function, CRP, ferritin, BNP, HbA1c, thyroid)when clinically indicatedNICE NG188, COVID-19 rapid guideline: managing the long-term effects of COVID-19, section 3 · checked Chest X-rayonce, by 12 weeks after acute COVID-19, if respiratory symptoms continueNICE NG188, COVID-19 rapid guideline: managing the long-term effects of COVID-19, section 3 · checked Home self-monitoring (heart rate, blood pressure, pulse oximetry, symptom diary)supported self-monitoring at home, as agreedNICE NG188, COVID-19 rapid guideline: managing the long-term effects of COVID-19, section 3 · checked

Lung cancer (5)

Contrast-enhanced brain MRI for stage 3 NSCLCstage 3 NSCLCNICE NG122 Lung cancer, diagnosis and staging · checked EBUS-TBNA biopsy of lung lesionsendobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)NICE NG122 Lung cancer, diagnosis and staging · checked Contrast-enhanced chest CTcontrast-enhanced chest CT scanNICE NG122 Lung cancer, diagnosis and staging · checked Pathology report with tumour subtype and molecular markerstumour subtyping and assessment of molecular markersNICE NG122 Lung cancer, diagnosis and staging · checked PET-CT before curative treatmentpositron emission tomography CT (PET-CT)NICE NG122 Lung cancer, diagnosis and staging · checked

Lupus (4)

ANA, anti-dsDNA, anti-Ro, anti-La, anti-RNP, anti-Sm, antiphospholipid antibodies, C3 and C4 at baselineat baseline: ANA, anti-dsDNA, anti-Ro, anti-La, anti-RNP, anti-Sm, anti-phospholipid, C3, C4EULAR recommendations for monitoring patients with SLE in clinical practice and in observational studies (Mosca et al., Ann Rheum Dis 2010), Table of recommendations · checked Blood cholesterol and glucose (cardiovascular risk check)at least once a yearEULAR recommendations for monitoring patients with SLE in clinical practice and in observational studies (Mosca et al., Ann Rheum Dis 2010), Table of recommendations · checked Routine labs in inactive disease: blood count, ESR, CRP, albumin, creatinine or eGFR, urinalysis, urine protein/creatinine ratioAt 6–12 months intervalsEULAR recommendations for monitoring patients with SLE in clinical practice and in observational studies (Mosca et al., Ann Rheum Dis 2010), Table of recommendations · checked Protein/creatinine ratio, C3, C4, anti-dsDNA, urine microscopy and blood pressure in lupus nephropathyat least every 3 months for the first 2–3 yearsEULAR recommendations for monitoring patients with SLE in clinical practice and in observational studies (Mosca et al., Ann Rheum Dis 2010), Table of recommendations · checked

Lyme disease (5)

Lyme ELISA blood testenzyme-linked immunosorbent assay (ELISA)NICE NG95 Lyme disease, recommendations · checked IgM and IgG antibody ELISA (C6 ELISA)both IgM and IgG antibodiesNICE NG95, Lyme disease, section 1.2 Diagnosis · checked Lyme immunoblot testimmunoblot testNICE NG95 Lyme disease, recommendations · checked Repeat Lyme ELISA 4 to 6 weeks after the first test4 to 6 weeks after the first ELISA testNICE NG95 Lyme disease, recommendations · checked Synovial fluid or cerebrospinal fluid analysissynovial fluid aspirate or biopsy, or lumbar puncture for cerebrospinal fluid analysisNICE NG95, Lyme disease, section 1.2 Diagnosis · checked

Lymphoma (4)

Integrated diagnostic report from a specialist haematological malignancy diagnostic service (SIHMDS)all new diagnosesNICE NG47, Haematological cancers: improving outcomes, recommendation 1.3.17 · checked FDG-PET-CT scan at the end of treatment for diffuse large B-cell or Burkitt lymphomaat completion of planned treatmentNICE NG52, Non-Hodgkin's lymphoma: diagnosis and management, recommendation 1.2.4 · checked Excision biopsy (histopathology) to diagnose non-Hodgkin lymphomaexcision biopsy as the first diagnostic procedureNICE NG52, Non-Hodgkin's lymphoma: diagnosis and management, recommendation 1.1.1 · checked FISH test of the lymphoma for an MYC rearrangement in high-grade B-cell lymphomaMYC rearrangementNICE NG52, Non-Hodgkin's lymphoma: diagnosis and management, recommendation 1.1.5 · checked

Macular degeneration (4)

Intravitreal anti-VEGF injection treatmentintravitreal anti-vascular endothelial growth factor (VEGF) treatmentNICE NG82, Age-related macular degeneration, recommendations · checked Fundus fluorescein angiography (FFA)to confirm the diagnosisNICE NG82, Age-related macular degeneration, recommendations · checked Optical coherence tomography (OCT) for suspected wet AMDoptical coherence tomography (OCT)NICE NG82, Age-related macular degeneration, recommendations · checked Ongoing OCT monitoring of both eyes in wet AMDongoing monitoringNICE NG82, Age-related macular degeneration, recommendations · checked

ME/CFS (3)

Primary care review of care and support plan, adultsat least once a yearNICE NG206 ME/CFS, recommendations · checked Review of care and support plan, children and young peopleat least every 6 monthsNICE NG206 ME/CFS, recommendations · checked Exclusion blood tests (vitamin D, vitamin B12 and folate levels, 9am cortisol)vitamin D, vitamin B12 and folate levelsNICE NG206 ME/CFS, recommendations · checked

Melanoma (3)

BRAF analysis of the melanoma tissue samplestage IIB to IV primary melanomaNICE NG14, Melanoma: assessment and management, recommendation 1.3.10 · checked Sentinel lymph node biopsy (histopathology) for staging melanomaBreslow thickness greater than 1.0 mmNICE NG14, Melanoma: assessment and management, recommendation 1.4.4 · checked Whole-body and brain contrast-enhanced CT during follow-up of stage IIC melanoma2 whole-body and brain CE CT scans each yearNICE NG14, Melanoma: assessment and management, table Follow-up after stages I to IV melanoma · checked

Menopause (4)

Serum FSH blood test to confirm menopauseonly in people aged 40 to 45NICE NG23, Menopause: identification and management, section 1.3 Identifying perimenopause and menopause · checked HRT prescription for vasomotor symptomsOffer HRTNICE NG23, Menopause: identification and management, section 1.9 Reviewing treatment for anyone · checked Review of each menopause treatment (HRT and other treatments)at 3 months ... annually thereafterNICE NG23, Menopause: identification and management, section 1.9 Reviewing treatment for anyone · checked Two FSH blood tests to diagnose premature ovarian insufficiency (under 40)2 blood samples taken 4 to 6 weeks apartNICE NG23, Menopause: identification and management, section 1.7 Diagnosing and managing premature ovarian insufficiency · checked

Migraine (4)

Headache diary for menstrual-related migrainefor at least 2 menstrual cyclesNICE CG150, Headaches in over 12s: diagnosis and management, section 1.1 · checked Headache diary to monitor treatmentongoing, to monitor treatmentNICE CG150, Headaches in over 12s: diagnosis and management, section 1.3 · checked Brain imaging for migraine: only when warning features develop, never solely for reassuranceneuroimaging solely for reassuranceNICE CG150, Headaches in over 12s: diagnosis and management, recommendations 1.3.2 and 1.3.3 · checked Review of migraine preventive medication after it is started3 to 6 months after starting prophylactic treatmentNICE CG150, Headaches in over 12s: diagnosis and management, recommendation 1.3.27 · checked

Multiple myeloma (3)

Bone marrow aspirate and trephine biopsy to confirm myelomabone marrow aspirate and trephine biopsyNICE NG35, Myeloma: diagnosis and management, recommendations · checked Monitoring tests for myeloma after treatment (blood count, kidney function, bone profile, immunoglobulins, protein electrophoresis)at least every 3 monthsNICE NG35, Myeloma: diagnosis and management, recommendations · checked Whole-body MRI as first-line imaging at diagnosisconsider whole-body MRI as first-line imagingNICE NG35, Myeloma: diagnosis and management, recommendations · checked

Multiple sclerosis (5)

Comprehensive MS care reviewat least once a yearNICE NG220, Multiple sclerosis in adults: management, comprehensive review · checked Cognition assessment in the comprehensive reviewas part of the person's comprehensive reviewNICE NG220, Multiple sclerosis in adults: management, comprehensive review · checked Review of fatigue medicineRegularly review treatmentNICE NG220, Multiple sclerosis in adults: management, spasticity · checked MRI of the brain and spinal cordat diagnosisNICE NG220, Multiple sclerosis in adults: management, diagnosis · checked Review of spasticity medicinesat least annually once the optimal dose has been reachedNICE NG220, Multiple sclerosis in adults: management, spasticity · checked

Myasthenia gravis (4)

Anti-acetylcholine receptor (AChR) antibody blood testAnti-AChR antibody testingShelly et al., National guidelines for diagnosis, treatment, and management of myasthenia gravis in Israel, Ther Adv Neurol Disord 2025 · checked MG-ADL patient-reported scaleMG-ADLShelly et al., National guidelines for diagnosis, treatment, and management of myasthenia gravis in Israel, Ther Adv Neurol Disord 2025 · checked Blood count and liver function monitoring on azathioprineregular monitoringShelly et al., National guidelines for diagnosis, treatment, and management of myasthenia gravis in Israel, Ther Adv Neurol Disord 2025 · checked Chest CT or MRI for thymomachest computed tomography (CT) or magnetic resonance imaging (MRI)Shelly et al., National guidelines for diagnosis, treatment, and management of myasthenia gravis in Israel, Ther Adv Neurol Disord 2025 · checked

Narcolepsy (5)

Actigraphy for 2 weeks before testingfor 2 weeks before testingKrahn et al., Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine, J Clin Sleep Med 2021 Multiple Sleep Latency Test (MSLT) report5 nap trialsKrahn et al., Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine, J Clin Sleep Med 2021 Overnight facility-based polysomnography before the MSLTthe night before the MSLTKrahn et al., Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine, J Clin Sleep Med 2021 Sleep diary for 2 weeks before testingfor 2 weeks before testingKrahn et al., Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine, J Clin Sleep Med 2021 Urine drug screen on the MSLT daywhen indicatedKrahn et al., Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine, J Clin Sleep Med 2021

Obesity (6)

Fasting blood glucosefasting blood glucoseKorean Society for the Study of Obesity, 2022 Update of Clinical Practice Guidelines for Obesity (J Obes Metab Syndr 2023), laboratory evaluation · checked Serum lipid profileserum lipid profileKorean Society for the Study of Obesity, 2022 Update of Clinical Practice Guidelines for Obesity (J Obes Metab Syndr 2023), laboratory evaluation · checked Liver function testsliver function testsKorean Society for the Study of Obesity, 2022 Update of Clinical Practice Guidelines for Obesity (J Obes Metab Syndr 2023), laboratory evaluation · checked Height, weight and waist circumference measurementsheight weight waist circumferenceNICE NG246 Overweight and obesity management, identifying and assessing · checked Weight-management medicine response check (prescription history)less than 5% of the initial weight has been lost after 6 monthsNICE NG246 Overweight and obesity management, medicines and surgery · checked Regular review of weight-management medicinesregular reviewNICE NG246 Overweight and obesity management, medicines and surgery · checked

OCD (3)

ECG and blood pressure before clomipraminebefore prescribing clomipramineNICE CG31, Obsessive-compulsive disorder and body dysmorphic disorder: treatment, recommendation 1.5.4.12 · checked SSRI prescription, reviewed after 12 months of remission12 months after remissionNICE CG31, Obsessive-compulsive disorder and body dysmorphic disorder: treatment, recommendation 1.5.3.16 · checked Written agreement on who monitors and treats the patient, copy given to the patientA written copy of this agreement should be given to the patientNICE CG31, Obsessive-compulsive disorder and body dysmorphic disorder: treatment, coordination of care · checked

Osteoarthritis (4)

Topical NSAID prescription for knee osteoarthritistopical non-steroidal anti-inflammatory drug (NSAID)NICE NG226 Osteoarthritis in over 16s, recommendations · checked Clinical diagnosis note (age 45 or over, activity-related joint pain)Diagnose osteoarthritis clinically without imagingNICE NG226 Osteoarthritis in over 16s, recommendations · checked Joint imaging (X-ray, MRI), not routineDo not routinely use imaging to diagnose osteoarthritisNICE NG226 Osteoarthritis in over 16s, recommendations · checked Treatment reviewfrequency of reviews on clinical needNICE NG226 Osteoarthritis in over 16s, recommendations · checked

Osteoporosis (4)

Baseline DXA bone density scan when starting treatmentbaselineNICE NG259, Osteoporosis: risk assessment, fragility fracture risk assessment · checked DXA-based vertebral fracture assessment (VFA)when doing a DXA scanNICE NG259, Osteoporosis: risk assessment, identifying vertebral fragility fractures · checked Oral bisphosphonate prescription (alendronate, ibandronate, risedronate)at least 5 yearsNational Osteoporosis Guideline Group, The 2024 UK clinical guideline for the prevention and treatment of osteoporosis, Arch Osteoporos 2025 · checked Routine blood tests at investigation (full blood count, vitamin D, thyroid function and others)Full blood cell countNational Osteoporosis Guideline Group, The 2024 UK clinical guideline for the prevention and treatment of osteoporosis, Arch Osteoporos 2025, Table 2 · checked

Ovarian cancer (3)

Serum CA125 blood test in suspected ovarian cancermeasure serum CA125NICE CG122, Ovarian cancer: recognition and initial management, recommendations · checked Tissue diagnosis by histology before chemotherapy for suspected advanced ovarian cancerconfirmed tissue diagnosis by histologyNICE CG122, Ovarian cancer: recognition and initial management, recommendations · checked Ultrasound of the abdomen and pelvis as first imaging in suspected ovarian cancerfirst imaging test in secondary careNICE CG122, Ovarian cancer: recognition and initial management, recommendations · checked

Pancreatic cancer (3)

Endoscopic ultrasound with tissue sampling when cytology or histology is neededoffer EUS with EUS‑guided tissue samplingNICE NG85, Pancreatic cancer in adults: diagnosis and management, recommendations · checked FDG-PET/CT for localised pancreatic cancer before treatmentoffer FDG-PET/CTNICE NG85, Pancreatic cancer in adults: diagnosis and management, recommendations · checked Pancreatic protocol CT scan for people with pancreatic abnormalities but no jaundicepancreatic protocol CT scanNICE NG85, Pancreatic cancer in adults: diagnosis and management, recommendations · checked

Parkinson's disease (4)

Levodopa prescription in early Parkinson's diseaseOffer levodopaNICE NG71 Parkinson's disease in adults, recommendations · checked 123I-FP-CIT SPECT (DaTscan)123 I-FP-CIT single photon emission computed tomography (SPECT)NICE NG71 Parkinson's disease in adults, recommendations · checked Structural MRI (not for diagnosis; for differential diagnosis)Structural MRI may be considered in the differential diagnosis of other parkinsonian syndromesNICE NG71 Parkinson's disease in adults, recommendations · checked Specialist review of diagnosisregular intervals of 6 to 12 monthsNICE NG71 Parkinson's disease in adults, recommendations · checked

PCOS (4)

Blood pressure measurementannuallyInternational evidence-based guideline for the assessment and management of PCOS 2023 (ESHRE, ASRM, Endocrine Society and partners) · checked Glycaemic status test (OGTT, fasting glucose or HbA1c)every one to three yearsInternational evidence-based guideline for the assessment and management of PCOS 2023 (ESHRE, ASRM, Endocrine Society and partners) · checked Fasting lipid profilefasting lipid profileInternational evidence-based guideline for the assessment and management of PCOS 2023 (ESHRE, ASRM, Endocrine Society and partners) · checked Oral glucose tolerance test (OGTT) when planning pregnancy24-28 weeksInternational evidence-based guideline for the assessment and management of PCOS 2023 (ESHRE, ASRM, Endocrine Society and partners) · checked

POTS (4)

Complete blood count and thyroid function testsfor selected patients2015 Heart Rhythm Society expert consensus statement on POTS, IST and vasovagal syncope, recommendations on investigation of POTS · checked 12-lead ECG with orthostatic vital signs at POTS assessmentshould be performed on patients being assessed for POTS2015 Heart Rhythm Society expert consensus statement on POTS, IST and vasovagal syncope, recommendations on investigation of POTS · checked Transthoracic echocardiogram (with tilt-table or autonomic testing in selected patients)may be considered for selected patients being assessed for POTS2015 Heart Rhythm Society expert consensus statement on POTS, IST and vasovagal syncope, recommendations on investigation of POTS · checked 24-hour Holter monitor (ambulatory ECG)may be considered for selected patients being assessed for POTS2015 Heart Rhythm Society expert consensus statement on POTS, IST and vasovagal syncope, recommendations on investigation of POTS · checked

Preeclampsia (4)

Full blood count, liver function and renal function blood teststwice a weekNICE NG133, Hypertension in pregnancy: diagnosis and management, table 2 Management of pregnancy with pre-eclampsia · checked Ultrasound assessment of the fetus (growth, amniotic fluid, umbilical artery doppler)at diagnosis and, if normal, repeat every 2 weeksNICE NG133, Hypertension in pregnancy: diagnosis and management, table 2 Management of pregnancy with pre-eclampsia · checked Placental growth factor (PLGF)-based testbetween 20 weeks and 36 weeks and 6 days of pregnancyNICE NG133, Hypertension in pregnancy: diagnosis and management, section 1.4 Gestational hypertension · checked Urinary reagent-strip (protein) test after the birth6 to 8 weeks after the birthNICE NG133, Hypertension in pregnancy: diagnosis and management, section 1.5 Pre-eclampsia, postnatal care · checked

Prostate cancer (5)

Isotope bone scan when hormonal therapy is deferredisotope bone scansNICE NG131 Prostate cancer, recommendations · checked Risk category assigned at diagnosis (Gleason grade, PSA, stage)assign a risk categoryNICE NG131 Prostate cancer, recommendations · checked Multiparametric prostate MRImultiparametric MRI as the first-line investigationNICE NG131 Prostate cancer, recommendations · checked PSA on intermittent androgen deprivation therapymeasure PSA every 3 monthsNICE NG131 Prostate cancer, recommendations · checked PSA blood test after radical treatmentat least every 6 months for the first 2 years, and then at least once a yearNICE NG131 Prostate cancer, recommendations · checked

Psoriasis (4)

Cardiovascular risk assessmentevery 5 yearsNICE CG153 Psoriasis: assessment and management, recommendations · checked PASI severity score and DLQI quality-of-life questionnairePsoriasis Area and Severity Index (PASI)NICE CG153 Psoriasis: assessment and management, recommendations · checked Annual psoriatic arthritis assessmentannualNICE CG153 Psoriasis: assessment and management, recommendations · checked Review of potent topical corticosteroid use (prescription history)at least annuallyNICE CG153 Psoriasis: assessment and management, recommendations · checked

Psoriatic arthritis (3)

Ultrasound of hands, feet and suspected enthesitis sitesultrasoundNICE NG65, Spondyloarthritis in over 16s: diagnosis and management, recommendations · checked Plain X-ray of symptomatic hands and feetplain film X-rayNICE NG65, Spondyloarthritis in over 16s: diagnosis and management, recommendations · checked PsARC response assessment on TNF inhibitor treatmentat 12 weeksNICE TA199, Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis · checked

PTSD (3)

Care plan agreed with the new service at each transition of carebefore a care plan has been agreed in the new serviceNICE NG116, Post-traumatic stress disorder, recommendation 1.2.5 · checked Venlafaxine or SSRI (such as sertraline) prescription for adults with PTSDReview this treatment regularlyNICE NG116, Post-traumatic stress disorder, recommendation 1.6.25 · checked Validated brief PTSD screening questionnaire after a major disasterat 1 month after the disasterNICE NG116, Post-traumatic stress disorder, recommendation 1.1.7 · checked

Pulmonary fibrosis (4)

Specialist follow-up reviewevery 3 months ... every 6 months ... annuallyNICE CG163, Idiopathic pulmonary fibrosis in adults: diagnosis and management, section 1.6 Review and follow-up · checked CT of the thorax with high-resolution imagesperforming CT of the thorax (including high-resolution images)NICE CG163, Idiopathic pulmonary fibrosis in adults: diagnosis and management, section 1.2 Diagnosis · checked Bronchoalveolar lavage, transbronchial biopsy or surgical lung biopsyconsider ... surgical lung biopsyNICE CG163, Idiopathic pulmonary fibrosis in adults: diagnosis and management, section 1.2 Diagnosis · checked Lung function tests (spirometry and gas transfer)diagnosis and 6 months and 12 months after diagnosisNICE CG163, Idiopathic pulmonary fibrosis in adults: diagnosis and management, section 1.4 Prognosis · checked

Rheumatoid arthritis (4)

Annual RA reviewannuallyNICE NG100, Rheumatoid arthritis in adults: management, section 1.8 · checked CRP blood test and DAS28 disease activity scoremonthly in specialist care until remission or low disease activityNICE NG100, Rheumatoid arthritis in adults: management, section 1.4 · checked Rheumatoid factor blood testat diagnosisNICE NG100, Rheumatoid arthritis in adults: management, section 1.1 · checked X-ray of hands and feetat diagnosisNICE NG100, Rheumatoid arthritis in adults: management, section 1.1 · checked

Sarcoidosis (5)

Baseline electrocardiogram (ECG)baseline ECGCrouser et al., Diagnosis and Detection of Sarcoidosis: An Official American Thoracic Society Clinical Practice Guideline, Am J Respir Crit Care Med 2020 · checked EBUS-guided lymph node sampling (tissue for histology)EBUS-guided lymph node samplingCrouser et al., Diagnosis and Detection of Sarcoidosis: An Official American Thoracic Society Clinical Practice Guideline, Am J Respir Crit Care Med 2020 · checked Baseline eye examinationa baseline eye examinationCrouser et al., Diagnosis and Detection of Sarcoidosis: An Official American Thoracic Society Clinical Practice Guideline, Am J Respir Crit Care Med 2020 · checked Baseline serum calcium testbaseline serum calcium testingCrouser et al., Diagnosis and Detection of Sarcoidosis: An Official American Thoracic Society Clinical Practice Guideline, Am J Respir Crit Care Med 2020 · checked Baseline serum creatinine testbaseline serum creatinine testingCrouser et al., Diagnosis and Detection of Sarcoidosis: An Official American Thoracic Society Clinical Practice Guideline, Am J Respir Crit Care Med 2020 · checked

Schizophrenia (4)

Baseline bloods before antipsychotics: glucose or HbA1c, lipid profile and prolactinBefore starting antipsychotic medicationNICE CG178, Psychosis and schizophrenia in adults: prevention and management, recommendation 1.3.6.1 · checked Clozapine prescription for treatment-resistant schizophreniaat least 2 different antipsychotic drugsNICE CG178, Psychosis and schizophrenia in adults: prevention and management, recommendation 1.5.7.2 · checked ECG before antipsychotic medication (when indicated)Before starting antipsychotic medicationNICE CG178, Psychosis and schizophrenia in adults: prevention and management, recommendation 1.3.6.2 · checked Fasting blood glucose or HbA1c, and blood lipids, on antipsychotic medicationat 12 weeks, at 1 year and then annuallyNICE CG178, Psychosis and schizophrenia in adults: prevention and management, recommendation 1.3.6.4 · checked

Sickle cell disease (5)

Chronic pain assessment (severity scale, location, effect on mood and activity)annuallyNHLBI Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014 · checked Serum ferritin in iron overloadSerum ferritin (SF) quarterlyNHLBI Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014 · checked Blood count with differential and reticulocytes on hydroxyureaat least every 4 weeksNHLBI Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014 · checked Urine protein screenrepeat screening annuallyNHLBI Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014 · checked Transcranial Doppler (TCD) ultrasoundscreen annually with TCDNHLBI Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014 · checked

Sjögren's syndrome (4)

Baseline blood tests for associated conditions (thyroid, liver, TTG, immunoglobulins, vitamin D and others)at baseline, and repeated as clinically indicatedBritish Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease, executive summary, Rheumatology (Oxford) 2025 · checked Hydroxychloroquine prescription6–12 monthsBritish Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease, executive summary, Rheumatology (Oxford) 2025 · checked Minor labial salivary gland biopsyminor labial salivary gland biopsyBritish Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease, executive summary, Rheumatology (Oxford) 2025 · checked Salivary gland ultrasoundUSS of the salivary glandsBritish Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease, executive summary, Rheumatology (Oxford) 2025 · checked

Sleep apnea (5)

Annual follow-up once CPAP is optimisedannual follow-upNICE NG202 Obstructive sleep apnoea/hypopnoea syndrome, recommendations · checked Home oximetryhome oximetryNICE NG202 Obstructive sleep apnoea/hypopnoea syndrome, recommendations · checked CPAP usage data (telemonitoring)up to 12 monthsNICE NG202 Obstructive sleep apnoea/hypopnoea syndrome, recommendations · checked Epworth Sleepiness Scale questionnaireEpworth Sleepiness ScaleNICE NG202 Obstructive sleep apnoea/hypopnoea syndrome, recommendations · checked Home respiratory polygraphy sleep studyhome respiratory polygraphyNICE NG202 Obstructive sleep apnoea/hypopnoea syndrome, recommendations · checked

Stroke (4)

Blood glucose readings during the acute stroke admissionbetween 4 and 11 mmol/litreNICE NG128, Stroke and transient ischaemic attack in over 16s: diagnosis and initial management, section 1 · checked Brain scan (CT or MRI) report after suspected strokewithin 24 hours of symptom onsetNICE NG128, Stroke and transient ischaemic attack in over 16s: diagnosis and initial management, section 1 · checked Carotid imaging reporturgent carotid imagingNICE NG128, Stroke and transient ischaemic attack in over 16s: diagnosis and initial management, section 1 · checked MRI report (diffusion-weighted and blood-sensitive sequences) after a TIAon the same day as the assessmentNICE NG128, Stroke and transient ischaemic attack in over 16s: diagnosis and initial management, section 1 · checked

Systemic sclerosis (scleroderma) (3)

HRCT and pulmonary function tests to detect lung disease in juvenile systemic sclerosisrepeat PFT at least 6 monthlyRheumatology (Oxford) 2024, The 2024 British Society for Rheumatology guideline for management of systemic sclerosis · checked Repeat pulmonary function tests in confirmed SSc interstitial lung diseaseevery 3–6 months in recently diagnosed SScRheumatology (Oxford) 2024, The 2024 British Society for Rheumatology guideline for management of systemic sclerosis · checked Annual screening for pulmonary arterial hypertension (lung function, echocardiography, NT-proBNP)annual basisRheumatology (Oxford) 2024, The 2024 British Society for Rheumatology guideline for management of systemic sclerosis · checked

Thyroid cancer (5)

Neck ultrasound after surgery without radioactive iodineat 6 to 12 months initiallyNICE NG230, Thyroid cancer: assessment and management, section 1.6 Follow-up of differentiated thyroid cancer · checked Thyroglobulin and thyroglobulin antibody blood tests3- to 6-month intervals in the first 2 years ... 6- to 12-month intervals thereafterNICE NG230, Thyroid cancer: assessment and management, section 1.5 Post-thyroidectomy monitoring · checked Fine-needle aspiration cytology (FNAC)offer fine-needle aspiration cytologyNICE NG230, Thyroid cancer: assessment and management, section 1.2 · checked Thyroid ultrasound with graded appearancethe initial diagnostic testNICE NG230, Thyroid cancer: assessment and management, section 1.2 · checked Thyroid hormone (levothyroxine) prescription at TSH-suppressing doseuntil follow-up review at 9 to 12 monthsNICE NG230, Thyroid cancer: assessment and management, section 1.4 TSH suppression · checked

Tinnitus (4)

Audiological assessment (hearing test)audiological assessmentNICE NG155, Tinnitus: assessment and management, recommendations · checked Insomnia Severity Index questionnaireInsomnia Severity IndexNICE NG155, Tinnitus: assessment and management, recommendations · checked MRI of the internal auditory meatiMRI (IAM)NICE NG155, Tinnitus: assessment and management, recommendations · checked Tinnitus Functional Index questionnaireTinnitus Functional IndexNICE NG155, Tinnitus: assessment and management, recommendations · checked

Type 1 diabetes (4)

Annual review of self-care and needsannuallyNICE NG17, Type 1 diabetes in adults: diagnosis and management · checked Continuous glucose monitoring (real-time or flash)a choice of real-time continuous glucose monitoring (rtCGM) or intermittently scanned continuous glucose monitoringNICE NG17, Type 1 diabetes in adults: diagnosis and management, recommendation 1.6.10 · checked Kidney tests (eGFR and urine albumin:creatinine ratio)annually, with cardiovascular risk assessmentNICE NG17, Type 1 diabetes in adults: diagnosis and management · checked HbA1c testevery 3 to 6 monthsNICE NG17, Type 1 diabetes in adults: diagnosis and management · checked

Type 2 diabetes (4)

Blood pressure measurementat least annuallyNICE NG136, Hypertension in adults: diagnosis and management, section 1.2 · checked Annual foot examination (diabetic foot risk check)annually for people at low risk, as part of the annual diabetes reviewNICE NG19, Diabetic foot problems: prevention and management · checked Diabetic eye screening (retinal photographs)at diagnosis, then through the national screening serviceNICE NG28, Type 2 diabetes in adults: management, section 1.43 Eye disease · checked HbA1c testevery 3 to 6 months until stable, then every 6 monthsNICE NG28, Type 2 diabetes in adults: management, section 1.5 HbA1c measurement and targets · checked

Ulcerative colitis (5)

Baseline colonoscopy with targeted biopsyonce, to set the surveillance riskNICE CG118, Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn's disease or adenomas · checked Surveillance colonoscopyevery 5 years (low risk), 3 years (intermediate risk), 1 year (high risk)NICE CG118, Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn's disease or adenomas · checked Review of biologic or JAK inhibitor treatmentat least every 12 monthsNICE NG130, Ulcerative colitis: management, section 1.2 · checked Bone health monitoring in children and young peopleduring chronic active diseaseNICE NG130, Ulcerative colitis: management, section 1.2 · checked Height and body weight on centile charts in children and young peopleevery 3 to 6 monthsNICE NG130, Ulcerative colitis: management, section 1.2 · checked

Vitiligo (3)

Screening for autoimmune and psychosocial comorbidities in vitiligomay require additional screeningDermatol Ther (Heidelb) 2025, Canadian Consensus Guidelines for the Management of Vitiligo · checked Dermatology Life Quality Index questionnaire in vitiligoDermatology Life Quality Index (DLQI)Dermatol Ther (Heidelb) 2025, Canadian Consensus Guidelines for the Management of Vitiligo · checked Reassessment of response during phototherapy for vitiligoreassessed periodicallyDermatol Ther (Heidelb) 2025, Canadian Consensus Guidelines for the Management of Vitiligo · checked

Share your health. Help find cures. Get paid. Health data for research, owned by the people who share it.

Product

Conditions
Value your data
Evidence
Guides
For research labs
Sign in

Legal

Privacy Policy
Terms of Service
Support

© 2026 CureCircle. All rights reserved.

Operated by O-mega Enterprise, Inc